[Trial of device that is not approved or cleared by the U.S. FDA] : [Trial of device that is not approved or cleared by the U.S. FDA]
The sickest patients with COVID-19 suffer a hyperinflammatory state-a cytokine storm-that has features in common with a rare haematological condition called haemophagocytic lymphohistiocytosis. Immune suppression should help such patients. By contrast, immune suppression during the early phase of the viral infection might allow increased viral replication and aggravate the disease.The 3C-like proteinase on SARS-CoV-2 (nsp5) inhibits HDAC2 transport into the nucleus, and so impairs the way in which it mediates inflammation and cytokine responses, so activation of histone deacetylase by dexamethasone may directly oppose the action of SARS-CoV-2.Timing of of corticosteroids administration is very important in COVID19 cases for the recovery and decrease the mortality..
| Medienart: |
|
|---|
Klinische Studie| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
ClinicalTrials.gov - (2022) vom: 04. Nov. Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: August 27, 2020, Last downloaded: ClinicalTrials.gov processed this data on November 07, 2022, Last updated: November 09, 2022 |
|---|
| Study ID: |
NCT04529616 |
|---|---|
| Veröffentlichungen zur Studie: |
|
| fisyears: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
CTG003500314 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | CTG003500314 | ||
| 003 | DE-627 | ||
| 005 | 20230425212625.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210408s2022 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)CTG003500314 | ||
| 035 | |a (UBBS_Klinische_Studien)NCT04529616 | ||
| 035 | |a (UBBS_Klinische_Studien)CSP-036 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a [Trial of device that is not approved or cleared by the U.S. FDA] |b [Trial of device that is not approved or cleared by the U.S. FDA] |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: August 27, 2020, Last downloaded: ClinicalTrials.gov processed this data on November 07, 2022, Last updated: November 09, 2022 | ||
| 520 | |a The sickest patients with COVID-19 suffer a hyperinflammatory state-a cytokine storm-that has features in common with a rare haematological condition called haemophagocytic lymphohistiocytosis. Immune suppression should help such patients. By contrast, immune suppression during the early phase of the viral infection might allow increased viral replication and aggravate the disease.The 3C-like proteinase on SARS-CoV-2 (nsp5) inhibits HDAC2 transport into the nucleus, and so impairs the way in which it mediates inflammation and cytokine responses, so activation of histone deacetylase by dexamethasone may directly oppose the action of SARS-CoV-2.Timing of of corticosteroids administration is very important in COVID19 cases for the recovery and decrease the mortality. | ||
| 650 | 4 | |a Recruitment Status: Withheld | |
| 650 | 4 | |a 610 | |
| 773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2022) vom: 04. Nov. |
| 773 | 1 | 8 | |g year:2022 |g day:04 |g month:11 |
| 856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT04529616 |z kostenfrei |3 Volltext |
| 912 | |a GBV_CTG | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2022 |b 04 |c 11 | ||